ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
12 announcements
Omkar Pharmachem Ltd has submitted its 31st Annual Report and Notice for the Annual General Meeting scheduled for September 30, 2026. The agenda includes approving audited accounts.
Omkar Pharmachem Ltd has scheduled its 31st Annual General Meeting for September 30, 2026. Key agenda items include adopting financial statements and approving material related party transactions.
Omkar Pharmachem Ltd has announced the outcome of its board meeting, including the schedule for its 31st Annual General Meeting and related party transactions approval.
Omkar Pharmachem Ltd reported revenue from operations of ₹0.1 Cr (+0.0% YoY) and net profit of ₹0 Cr for Q1 FY27.
Omkar Pharmachem will hold a board meeting on August 13, 2026, to consider and approve the unaudited financial results for the quarter ended June 30, 2026.
Omkar Pharmachem Ltd filed its quarterly shareholding pattern for the period ending June 30, 2026. The filing includes a request regarding missing PAN details for some shareholders.
Omkar Pharmachem Ltd reported audited financial results for the fiscal year ended March 31, 2026. The Board approved the statements including a full P&L and balance sheet.
Omkar Pharmachem Ltd reported revenue from operations of ₹0.1 Cr (+0.0% YoY) and net profit of ₹0 Cr for Q4 FY26.
Omkar Pharmachem approved audited financial results for FY26, reporting a total income of ₹0.47 Crore. The company posted a net profit of ₹0.12 Crore for the year.
Omkar Pharmachem submitted its Annual Secretarial Compliance Report for the year ended March 31, 2026. The report confirms overall regulatory compliance with no major deviations recorded.
Omkar Pharmachem scheduled a board meeting for May 30, 2026, to approve audited financial results. The trading window remains closed for designated persons until June 1.
Omkar Pharmachem announced a minor name spelling change for Managing Director Bhawani S Goyal. His designation and responsibilities remain unchanged, representing a purely administrative update.